Dr. Kahwaji is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4760 W Sunset Blvd
Los Angeles, CA 90027Phone+1 323-783-4011Fax+1 626-405-6768
Education & Training
- UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Transplant Nephrology, 2007 - 2008
- Kaiser Permanente Southern California (Los Angeles)Fellowship, Nephrology, 2005 - 2007
- Kaiser Permanente Southern California (Los Angeles)Residency, Internal Medicine, 2002 - 2005
- Medical College of WisconsinClass of 2002
Certifications & Licensure
- CA State Medical License 2003 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Nephrology
Clinical Trials
- Role of Everolimus in Highly Sensitized Patients Start of enrollment: 2013 Jun 01
- C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI Start of enrollment: 2014 Sep 01
Publications & Presentations
PubMed
- Bisphosphonate Use after Kidney Transplantation Is Associated with Lower Fracture Risk.Joseph M Kahwaji, Su-Jau Yang, John J Sim, Chong Young Parke, Roland L Lee
Clinical Journal of the American Society of Nephrology. 2024-11-05 - 4 citationsBelatacept Conversion Protocols and Outcomes in Kidney Transplant Recipients.Mona Yazdi, Joseph M. Kahwaji, Sam Meguerditchian, Roland Lee
Transplantation Proceedings. 2021-04-01 - 42 citationsPlasma Exosomes From HLA-Sensitized Kidney Transplant Recipients Contain mRNA Transcripts Which Predict Development of Antibody-Mediated Rejection.Hao Zhang, Edmund Huang, Joseph Kahwaji, Cynthia C. Nast, Ping Li
Transplantation. 2017-10-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: